Ketoprofen Sales

Ketoprofen Sales Market Outlook

The global ketoprofen sales market is projected to reach approximately USD 1.5 billion by 2035, growing at a compound annual growth rate (CAGR) of around 5.2% during the forecast period from 2025 to 2035. This steady growth is primarily attributed to the rising prevalence of conditions requiring pain relief and inflammation management, such as arthritis and musculoskeletal disorders, along with increased demand for effective non-steroidal anti-inflammatory drugs (NSAIDs). Additionally, the growing awareness surrounding pain management alternatives and the expanding pharmaceutical industry globally contribute significantly to the market's expansion. The surge in online pharmacies and e-commerce platforms is also expected to enhance accessibility for consumers, further driving market growth. Furthermore, advancements in drug formulation and delivery methods are anticipated to fuel the development of new ketoprofen-based products, catering to a broader range of patient needs.

Growth Factor of the Market

One of the most significant growth factors for the ketoprofen sales market is the increasing incidence of chronic pain conditions, particularly among the aging population. As the global population ages, the prevalence of conditions such as osteoarthritis and rheumatoid arthritis rises, necessitating the need for effective pain relief solutions like ketoprofen. In addition, the growing emphasis on improved healthcare and pain management strategies among healthcare professionals is driving the demand for NSAIDs, including ketoprofen. Furthermore, the rise in lifestyle-related issues, such as obesity and sedentary behavior, has led to an increase in musculoskeletal disorders, thereby boosting the need for potent pain management options. The expansion of over-the-counter (OTC) ketoprofen formulations is also contributing to market growth, as consumers increasingly seek relief from pain and inflammation without the need for a prescription. Lastly, the increasing penetration of e-commerce channels in pharmaceuticals offers patients greater access to ketoprofen products, thereby facilitating market growth.

Key Highlights of the Market

• The global ketoprofen market is expected to grow at a CAGR of 5.2% between 2025 and 2035.
• North America holds the largest share of the ketoprofen market due to high demand for pain management products.
• Tablets and capsules are the dominant product types in the ketoprofen segment.
• Online pharmacies are rapidly gaining traction as a preferred distribution channel among consumers.
• Ketoprofen's efficacy in treating various pain-related conditions drives its application in multiple therapeutic areas.

By Product Type

Tablets:

Tablets represent one of the most common forms of ketoprofen products available in the market. This modality is favored due to its ease of administration and precise dosage, making it a preferred choice for patients and healthcare providers alike. The bioavailability and rapid onset of action attributed to oral tablets are significant factors driving their popularity. Tablets are often prescribed for various conditions requiring pain management and inflammation control, leading to a substantial market share in the ketoprofen segment. Furthermore, the availability of over-the-counter variants enhances patient accessibility, thus promoting greater adoption of this product type in pain management therapies.

Capsules:

Capsules are another significant product type within the ketoprofen market. They offer various advantages over traditional tablets, including potential enhanced absorption and a more efficient delivery system for the active ingredients. The gelatin-based composition of capsules allows for a more convenient swallowing experience for patients who may have difficulty with tablets. Additionally, the unique formulation potential of capsules allows for the encapsulation of multiple ingredients or pairing with other medications for synergistic effects, such as ketoprofen with paracetamol. As a result, capsules are becoming increasingly popular among consumers seeking effective pain relief solutions.

Topical Gel:

Topical gel formulations of ketoprofen have gained traction due to their localized application and reduced systemic exposure. These gels are particularly beneficial for patients suffering from localized musculoskeletal pain or inflammation, enabling targeted relief without the side effects associated with systemic administration. The ease of application and rapid absorption of topical gels make them an attractive choice for consumers who prioritize convenience and effectiveness. Furthermore, the growing trend of self-care and home-based treatments is propelling the demand for topical formulations, as more patients seek alternatives to oral medications for their discomfort.

Topical Cream:

Topical creams containing ketoprofen are widely used due to their skin-friendly formulation and ease of use. Similar to topical gels, these creams are applied directly to the site of pain or inflammation, providing localized relief while minimizing the risk of systemic side effects. The soothing texture and moisturizing properties of creams also enhance patient comfort, making them a preferred choice for long-term pain management practices. With increasing awareness about the benefits of topical treatments for conditions such as arthritis and sports injuries, the market for ketoprofen topical creams is expected to witness significant growth.

Injections:

Injectable formulations of ketoprofen cater to patients requiring rapid pain relief or those unable to take oral medications due to various reasons. This product type is particularly prevalent in hospital and clinical settings, where healthcare professionals administer injections for immediate therapeutic effects. The fast onset of action associated with injectable ketoprofen makes it invaluable in emergency situations or for post-operative pain management. As healthcare moves towards personalized medicine, the injectable segment is expected to expand, with innovations such as long-acting formulations and combination therapies enhancing their clinical utility.

By Application

Pain Management:

Pain management is one of the most significant applications for ketoprofen, given its classification as a non-steroidal anti-inflammatory drug (NSAID) that effectively alleviates various types of pain. This application encompasses acute pain from injuries, chronic pain from conditions like arthritis, and post-operative pain management. The increasing prevalence of chronic pain disorders, especially in aging populations, is driving the demand for effective pain relief medications like ketoprofen. Moreover, healthcare providers are increasingly prescribing ketoprofen due to its proven efficacy in pain reduction, leading to a strong market presence in this application segment.

Inflammation Treatment:

Inflammation treatment is another critical application area for ketoprofen, as it is well-known for its anti-inflammatory properties. Conditions such as rheumatoid arthritis, osteoarthritis, and other inflammatory diseases necessitate effective management strategies to reduce inflammation and improve patient quality of life. Ketoprofen's ability to inhibit the production of inflammatory mediators has made it a preferred choice among healthcare professionals for managing these conditions. The rising incidence of inflammatory disorders globally, combined with the need for effective treatment options, is expected to bolster the growth of this application segment.

Fever Reduction:

Ketoprofen is also utilized for fever reduction, making it a versatile analgesic and anti-inflammatory agent. In pediatric and adult populations, the drug is employed to manage fever associated with various infections or illnesses. The ability to provide rapid relief from fever symptoms enhances ketoprofen's appeal among patients and caregivers seeking effective symptomatic treatment options. As awareness regarding fever management grows, particularly in the context of rising global health concerns, the market for ketoprofen in fever reduction is likely to see continued expansion.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a vital role in the distribution of ketoprofen, particularly in clinical settings where immediate access to medications is crucial. These pharmacies typically provide injectable and prescription formulations of ketoprofen used in acute care settings such as emergency rooms and surgical recovery areas. The extensive network of healthcare professionals within hospitals ensures the appropriate use of ketoprofen among patients requiring pain management and anti-inflammatory therapy. As healthcare systems become more integrated and focused on patient-centered care, the significance of hospital pharmacies in the ketoprofen sales market is expected to grow further.

Retail Pharmacies:

Retail pharmacies are essential distribution channels for ketoprofen, as they provide over-the-counter access to patients seeking relief from various pain and inflammatory conditions. The convenience of purchasing ketoprofen formulations such as tablets and topical creams from local pharmacies enhances consumer accessibility. Furthermore, retail pharmacies often engage in health promotion and education, guiding patients on the appropriate use of ketoprofen and raising awareness of its benefits. As consumers increasingly prioritize self-medication and health management, the retail pharmacy segment is anticipated to witness robust growth in ketoprofen sales.

Online Pharmacies:

Online pharmacies have experienced significant growth in recent years, largely due to the increasing preference for e-commerce and the convenience it offers patients. The ability to purchase ketoprofen products online enables consumers to avoid in-person visits to pharmacies, which is particularly attractive for individuals with mobility issues or those living in remote areas. Additionally, online pharmacies often provide competitive pricing and promotions, further incentivizing consumer purchases. The pandemic has accelerated the adoption of online pharmacies, and this trend is expected to continue driving the market for ketoprofen as more patients opt for digital access to medications.

By Ingredient Type

Ketoprofen with Paracetamol:

Ketoprofen combined with paracetamol offers a synergistic approach to pain management, effectively addressing various types of pain while minimizing the risks associated with high doses of individual medications. The combination enhances analgesic efficacy, making it suitable for conditions that require stronger pain relief, such as post-surgical pain or severe arthritis. The growing acceptance and demand for combination therapies are expected to propel the growth of ketoprofen with paracetamol in the market, attracting patients seeking comprehensive pain management solutions.

Ketoprofen with Ibuprofen:

The combination of ketoprofen with ibuprofen offers a dual mechanism of action that enhances anti-inflammatory and analgesic effects. This combination is particularly beneficial for patients who have not responded adequately to monotherapy with either medication. By providing a broader spectrum of pain and inflammation relief, ketoprofen with ibuprofen is increasingly being prescribed for conditions like rheumatoid arthritis and osteoarthritis. The rising trend towards personalized medicine further supports the growth of this ingredient type as it allows for tailored pain management strategies that consider individual patient needs.

Ketoprofen with Diclofenac:

Ketoprofen with diclofenac represents a powerful combination for managing severe pain and inflammation. Both are NSAIDs known for their efficacy, and their combined use can provide enhanced therapeutic benefits for patients suffering from chronic inflammatory conditions. The synergy between these two active ingredients allows for lower dosing of each individual component, potentially reducing side effects associated with higher doses. The increasing prevalence of inflammatory diseases globally is driving interest in combination therapies like ketoprofen with diclofenac, making it a promising segment of the market.

Ketoprofen with Naproxen:

The combination of ketoprofen with naproxen is another effective treatment option for managing acute and chronic pain. Both medications belong to the NSAID class, and their combined use can provide a more robust analgesic effect, particularly for patients with conditions such as osteoarthritis or acute musculoskeletal injuries. This combination therapy is attractive for patients seeking comprehensive pain management solutions while minimizing the risk of gastrointestinal side effects typically associated with high doses of NSAIDs. As the market for innovative pain management solutions expands, ketoprofen with naproxen is likely to see increased adoption among patients and healthcare providers.

Ketoprofen with Lidocaine:

Ketoprofen with lidocaine is a unique combination that offers localized pain relief, particularly in cases of acute pain or localized inflammation. Lidocaine, being a local anesthetic, provides immediate relief from pain upon application, while ketoprofen addresses the underlying inflammation. This combination is particularly valuable in topical formulations, allowing for targeted treatment of conditions such as sports injuries, arthritis flare-ups, or postoperative pain management. As patients continue to seek effective non-invasive pain relief options, the segment of ketoprofen with lidocaine is expected to experience notable growth in the market.

By Region

The ketoprofen sales market is segmented geographically into key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America currently dominates the market, accounting for approximately 40% of the global ketoprofen sales revenue. This is driven by the high prevalence of chronic pain conditions, increased healthcare expenditures, and a robust pharmaceutical distribution network. The increasing adoption of over-the-counter NSAIDs in the U.S. further contributes to the significant market share held by North America. Europe follows closely as the second-largest region, with a growing demand for ketoprofen driven by rising awareness of pain management options and increased rates of conditions requiring anti-inflammatory treatments.

In the Asia Pacific region, the ketoprofen sales market is anticipated to grow at the highest CAGR of around 6.0% during the forecast period from 2025 to 2035. This growth can be attributed to the rising burden of various chronic diseases, increasing disposable incomes, and improvements in healthcare infrastructure. Countries like China and India are witnessing a significant rise in demand for analgesics due to changing lifestyles and an aging population. Conversely, Latin America and the Middle East & Africa are expected to see steady growth, driven by increased access to healthcare and rising awareness of treatment options, although they currently represent a smaller portion of the global market. The overall regional dynamics indicate a bright outlook for ketoprofen sales across these diverse markets, each contributing to the anticipated growth during the forecast period.

Opportunities

The ketoprofen sales market presents numerous opportunities for growth, particularly through advancements in product formulation and delivery systems. As pharmaceutical companies continue to innovate, the development of new formulations that enhance the efficacy and reduce the side effects of ketoprofen can significantly boost market demand. The trend towards personalized medicine is also opening avenues for tailoring ketoprofen therapies to individual patient needs, enhancing treatment outcomes. Furthermore, the increasing acceptance of online pharmacies provides an opportunity for manufacturers to reach a broader audience, particularly among younger consumers who prefer e-commerce for medication purchases. This shift towards digital distribution channels could result in increased sales volumes for ketoprofen products, ultimately driving market growth.

Another area of opportunity lies in expanding the therapeutic applications of ketoprofen. Research into its potential efficacy in treating conditions beyond traditional uses, such as neuropathic pain or specific surgical pain management scenarios, can unlock new market segments. Additionally, collaborations between pharmaceutical companies and healthcare providers to educate patients about the benefits of ketoprofen and its various formulations can enhance visibility and boost demand. As awareness about pain management continues to grow globally, leveraging these opportunities can significantly enhance the ketoprofen sales market's prospects in the coming years. Overall, the market is well-positioned to capitalize on these emerging opportunities, leading to sustained growth and innovation.

Threats

Despite the promising growth trajectory, the ketoprofen sales market faces several threats that could impact its future development. One significant threat is the increasing competition from alternative pain management therapies, including opioids, which may provide immediate relief for some patients. Although opioids come with their own set of risks and side effects, their potent analgesic effects may lead some healthcare providers to prefer them over NSAIDs like ketoprofen. This shift in prescribing practices could hinder the market's growth as patients turn to these alternatives. Furthermore, the growing concerns regarding the safety profile of NSAIDs, including potential gastrointestinal and cardiovascular risks, may lead to stricter regulations and reduced prescriptions from healthcare professionals, further posing a threat to the ketoprofen market.

Additionally, the presence of counterfeit or substandard medications in some regions poses a significant challenge to the integrity of the ketoprofen market. Patients may unknowingly purchase ineffective or harmful products, leading to negative health outcomes and diminished trust in ketoprofen as a treatment option. This issue could ultimately discourage patients from using ketoprofen and drive them towards alternative medications. Moreover, economic downturns and fluctuating healthcare budgets, particularly in developing regions, could restrict access to essential medications, hindering sales growth for ketoprofen. As the market navigates these threats, it will be crucial for stakeholders to develop strategies that ensure product integrity, patient education, and continued innovation to maintain a competitive edge.

Competitor Outlook

• Pfizer Inc.
• Roche Holding AG
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• GlaxoSmithKline plc
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Amgen Inc.
• AbbVie Inc.
• Hikma Pharmaceuticals PLC
• AstraZeneca PLC
• Dr. Reddy's Laboratories Ltd.
• Alvogen, Inc.
• Fresenius Kabi AG
• Cadila Healthcare Ltd.

The competitive landscape of the ketoprofen sales market is characterized by a mix of global pharmaceutical giants and regional players vying for market share. Major companies such as Pfizer Inc., Roche Holding AG, and Novartis AG hold significant portions of the market due to their strong research and development (R&D) capabilities, comprehensive product portfolios, and established distribution networks. These companies are continually innovating to enhance existing formulations and explore new therapeutic applications for ketoprofen, which helps them maintain their competitive edge. Additionally, their robust marketing strategies and brand recognition serve to solidify their positions within the market, ensuring that their ketoprofen products remain top-of-mind for healthcare providers and patients alike.

Emerging players and generics manufacturers are also gaining traction in the ketoprofen sales market, driven by the demand for cost-effective alternatives to brand-name medications. Companies like Teva Pharmaceutical Industries, Mylan, and Sun Pharmaceutical Industries are leveraging their experience in the generics sector to provide affordable ketoprofen formulations, catering to budget-conscious consumers and healthcare systems. The increasing acceptance of generic medications in many regions is likely to intensify competition and lead to price reductions across the market. This dynamic can lead to increased accessibility and utilization of ketoprofen, benefiting patients while challenging established brands to enhance their value propositions.

The future of the ketoprofen sales market will be shaped by ongoing collaborations and partnerships among key industry players and healthcare providers. Strategic alliances aimed at research, distribution, and education initiatives can enhance product visibility and effectiveness in pain management. Companies that focus on developing innovative formulations, such as combination products or sustained-release versions of ketoprofen, are expected to gain a competitive advantage in the years to come. Overall, the competitive landscape is vibrant, with both established companies and emerging players working to capitalize on the growing demand for effective pain relief solutions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi S.A.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Alvogen, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 AstraZeneca PLC
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Roche Holding AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Fresenius Kabi AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Cadila Healthcare Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Hikma Pharmaceuticals PLC
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Dr. Reddy's Laboratories Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Sun Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis
  • 5.16 Teva Pharmaceutical Industries Ltd.
    • 5.16.1 Business Overview
    • 5.16.2 Products & Services
    • 5.16.3 Financials
    • 5.16.4 Recent Developments
    • 5.16.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Ketoprofen Sales Market, By Application
    • 6.1.1 Pain Management
    • 6.1.2 Inflammation Treatment
    • 6.1.3 Fever Reduction
  • 6.2 Ketoprofen Sales Market, By Product Type
    • 6.2.1 Tablets
    • 6.2.2 Capsules
    • 6.2.3 Topical Gel
    • 6.2.4 Topical Cream
    • 6.2.5 Injections
  • 6.3 Ketoprofen Sales Market, By Ingredient Type
    • 6.3.1 Ketoprofen with Paracetamol
    • 6.3.2 Ketoprofen with Ibuprofen
    • 6.3.3 Ketoprofen with Diclofenac
    • 6.3.4 Ketoprofen with Naproxen
    • 6.3.5 Ketoprofen with Lidocaine
  • 6.4 Ketoprofen Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Ketoprofen Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Ketoprofen Sales market is categorized based on

By Product Type

• Tablets
• Capsules
• Topical Gel
• Topical Cream
• Injections

By Application

• Pain Management
• Inflammation Treatment
• Fever Reduction

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Ketoprofen with Paracetamol
• Ketoprofen with Ibuprofen
• Ketoprofen with Diclofenac
• Ketoprofen with Naproxen
• Ketoprofen with Lidocaine

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Roche Holding AG
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• GlaxoSmithKline plc
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Amgen Inc.
• AbbVie Inc.
• Hikma Pharmaceuticals PLC
• AstraZeneca PLC
• Dr. Reddy's Laboratories Ltd.
• Alvogen, Inc.
• Fresenius Kabi AG
• Cadila Healthcare Ltd.